| Sex (M/F) |
31/19 |
| Age, years (mean, 95% CI) |
46 (39 ∼52.4) |
| Disease duration (median, IQR) |
3.5 (2–6) |
| Disease distribution (E1/E2/E3) |
13∕20∕17 (26%/40%/34%) |
| Smoking status (nonsmoker/current smoker/ever-smoker) |
34∕4∕12 (68%/8%/24%) |
| Current medication |
|
| − steroid (Y/N) |
17/33 (34%/66%) |
| − oral 5-ASA (Y/N) |
47/3 (94%/6%) |
| − rectal 5-ASA (Y/N) |
27/23 (54%/47%) |
| − immune modulator (Y/N) |
12/38 (24%/76%) |
| - biologic agent (Y/N) |
1/49 (2%/98%) |
| WBC count, 103/µL (median, IQR) |
6.5 (5.6–7.4) |
| Hemoglobin level, g/dL (median, IQR) |
14.15 (13.26–14.6) |
| Platelet count,103/µL (median, IQR) |
261 (229.83–295.95) |
| NLR (median, IQR) |
2.26 (1.84–2.74) |
| CRP level, mg/dL (median, IQR) |
0.13 (0.09 –0.24) |
| ESR, mm/h (median, IQR) |
10 (8–13.8) |
| Endoscopy Mayo score (0/1/2/3) |
15/16/8/11(30%/32%/16%/22%)) |
| iFOBT, ng/ml (median, IQR) |
44.5 (7–101.7) |
| FC, µg/g (median,IQR) |
135.88 (83.06–651.6) |
